人类白细胞抗原G研究进展及与呼吸系统疾病相关性

人类白细胞抗原G是非经典的人类白细胞抗原I类分子,具有复杂的免疫耐受功能.最近有研究表明在一些实体瘤、病毒感染的细胞、移植器官和表皮炎性疾病中都有其表达.该文对人类白细胞抗原G的基因结构、生物学功能、组织分布等方面的最新研究进展及与呼吸系统疾病的相关性作一综述.     

Preoperative Cell-Mediated Immune Status of Patients with Malignant Glial Tumors

The leukocyte adherence inhibition assay (LAI) was used to measure cell-mediated immunity in 26 patients with malignant glial neoplasms and in 41 control subjects. A significant inhibition of leukocyte adherence was observed in 21 out of 26 (80%) patients with malignant astrocytic gliomas in the presence of a 3M KC1 extract of glioma tissue compared to that of normal brain extract. Among the control group, no significant difference in the percentage of nonadherent leukocytes (NAL) was noted in the presence of either antigen. To study the specificity of the reaction, 3M KC1 extracts of meningioma, pituitary tumor, carcinoma of breast, carcinomas of lung, melanoma, brain, and heart tissues were employed as nonspecific antigens. Such studies revealed significantly lower values of NAL.

These data indicate that patients with malignant glial neoplasms manifest a cellular-immune response to glioma-associated antigens that can be measured by the tube LAI assay and that LAI assay may render additional useful information in the diagnostic and prognostic evaluation of malignant glial neoplasms.     

Genetics in multiple sclerosis: past and future perspectives

The enormous development in the field of molecular genetics during the last decades has lead to optimism concerning the possibilities for identifying the causes of multiple sclerosis (MS) through genetic studies. However, we have learned that dense mapping of large sample sets is needed, which only can be achieved through large collaborative studies. The contribution from each yet unidentified gene is probably weaker than that of the well established human leukocyte antigen association. The ultimate goal of the search for susceptibility genes in MS is to develop diagnostic tools and better treatments that can prevent or reduce the development of symptoms of this often devastating disease.     

大鼠脑缺血再灌注区ICAM—1的表达与粘附性变化的实验研究

目的:观察大鼠脑缺血再灌注后缺血区ＩＣＡＭ－１ｍＲＮＡ和蛋白的表达及白细胞和血管内皮细胞间粘附性的变化。方法:４０只Ｗｉｓｔａｒ大鼠分为正常组、假手术组和缺血２ｈ再灌注２、４、１２、２４、４８、９６ｈ组,原位杂交和兔疫组化法检测ＩＣＡＭ、１ ｍＲＮＡ和蛋白表达,超高速摄录像系统观察缺血区微血管内白细胞与内皮细胞间的粘附性变化。结果:缺血再灌注后局部脑组织ＩＣＡＭ－１ｍＲＮＡ和蛋白的表达以及微动脉内白细胞与内皮细胞间粘附性均明显增高。结论:脑缺血再灌注后ＩＣＡＭ－１表达增高,介导了白细胞与血管内皮细胞间的粘附增强,参与了缺血再灌注损伤。     

A patient with a <Emphasis Type="Italic">Mycobacterium avium</Emphasis> complex infection complicated by systemic lupus erythematosus

A 41-year-old woman was admitted to our hospital because of fever and polyarthralgia. A diagnosis of systemic lupus erythematosus (SLE) was made based on the findings of polyarthritis, leukocytopenia, lymphocytopenia, proteinuria, and positive reactions for antinuclear antibody (ANA) and anti-double strand (ds)DNA antibody. She had also been suffering from a pulmonary Mycobacterium avium complex (MAC) infection with such symptoms as cough and sputum for the past 3 years. Antimicrobial drugs for MAC infection were administered first, and later she was given cyclophosphamide pulse therapy, consisting of methylprednisolone (8mg/day) and mizoribine (100mg/day). Owing to these therapeutic regimens, SLE was successfully treated without an exacerbation of the MAC infection. The risk factors for MAC infection and SLE are also discussed.     

牙龈卟啉单胞菌rag位点基因分型与细菌毒力的关系研究

目的：探讨牙龈卟啉单胞菌rag位点基因分型与细菌毒性的关系。方法将不同rag基因位点的牙龈卟啉单胞菌W83(rag-1型)、A011/9(rag-2型)、QM220(rag-3型)和ATCC33277(rag-4型)菌株分别刺激中性多形核白细胞,未受刺激的中性多形核白细胞作为对照。采用RT-PCR检测FcγⅢb受体基因,流式细胞术检测中性多形核白细胞凋亡情况,试剂盒检测毒力因子。结果 W83组 FcγⅢb基因相对表达量显著高于其他组( P <0．05),其次为QM220组,显著高于A011/9和ATCC33277组(P<0.05)。流式细胞术检测发现,ATCC33277组细胞凋亡率显著高于其他各组(P<0.05),A011/9组凋亡率显著高于W83组(P<0.05)。各基因分型组LPS、LBP、mCD14、MMP-8 MMP-9、IL-8以及IL-1β均高于对照组(P<0.05)。W83组上述指标显著高于其他各基因型组(P<0.05),QM220组次之,与 A011/9、ATCC33277组比较差异有统计学意义(P <0.05)。 A011/9组在 LPS、LBP、mCD14方面高于ATCC33277组(P<0.05),而MMP-8、MMP-9两者差异无统计学意义(P>0.05)。结论牙龈卟啉单胞菌菌株中rag位点基因分型的细菌毒性rag-1型最强,rag-3型次之,较弱的为rag-2型和rag-4型。     

Urinary organ specific neoantigen

Urinary organ-specific neoantigen from colorectal cancer patients has been used to make a monoclonal antibody, BAC 18.1. In this study we assessed the potential of this antibody for the diagnosis of colorectal cancer. We evaluated binding in both urine and effluent samples and compared it with effluent carcinoembryonic antigen standardized for both volume (nanograms per milliliter) and protein. Urinary organ-specific antigen as detected by BAC 18.1 was significantly greater in 29 cancer patients (A₄₀₅:0.717±0.500) vs 27 controls [0.121 ±0.273 (P<0.05)]. Considerable overlap of binding of BAC 18.1 was observed in the colonic effluent of patients with CRC (N=13), adenomas (N=26), inflammatory bowel disease (N=8), or having a normal colonoscopic examination (N=24). CEA levels (nanograms per milliliter) were significantly elevated in the effluent samples of patients with a past history of colorectal cancer, as compared to that of normal individuals (P<0.05). The presence of the Mr 30,000 organ-specific neoantigen in colonic effluent was also demonstrated by western blot. Organ-specific neoantigen originates in the colon and is excreted into the urine, so the BAC 18.1 binding levels in the urine may be a diagnostic aid for CRC.The work reported in this paper was supported in part by a grant from the Israeli Cancer Association and Tel Aviv University, and in part by grants from the Israel Cancer Association and the Sackler School of Medicine, Tel Aviv, Israel.     

Soluble HLA-I (s-HLA-I) synthesis in systemic lupus erythematosus

Our objective was to study a possible contribution of major histocompatibility complex (MHC) genes to soluble HLA-I synthesis in patients with systemic lupus erythematosus (SLE). Solid-phase enzyme-linked immunoassay (ELISA) was used to measure sHLA-I in the sera of 20 patients with SLE and 76 normal controls with known HLA phenotypes. Serial serum samples (n=108) from the above group of patients (n=19) were further investigated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. Soluble HLA-I levels were abnormally higher in patients with SLE than normal controls (P<0.0002). No complete HLA haplotype has been identified to be correlated with high or low sHLA-I secretion. Only the sera of HLA-A23- or -A24- (splits of HLA-A9) positive individuals were found to contain high sHLA-I concentrations in both populations studied. The difference between sHLA-I of HLA-A24 patients (n=7) and HLA-A24 normal controls (n=19) was statistically highly significant (P<0.0079). The results suggest that HLA-A24 may confer additional risk of more severe disease expression in female patients with SLE. The data imply that SLE patients carrying 39-kDa sHLA-I have increased risk of developing renal disease. A higher prevalence of 35–37 kDa was observed in patients with mild disease. Interestingly, 44–46 kDa was the predominant molecular form of sHLA-I in SLE patients with lymphocytosis with no evidence of organ involvement. Notably, all these variations were not reflected by differences in HLA phenotypes, with the exception of HLA-A24-positive patients, in whom the 44–46-kDa form occurs consistently but not exclusively. In summary, the results show a genetic heterogeneity of SLE with MHC control of the expression of sHLA-I concentrations and possible involvement of disease-associated factors that might potentiate a specific sHLA-I molecule synthesis.